February 23, 2011
Researchers from the University of California, San Francisco, and Johns Hopkins University are recruiting patients to examine whether a drug prescribed to treat alcohol and cocaine addiction can reduce the amount of latent HIV among HIV-positive patients already taking combination therapy, Bloomberg reports. "The researchers plan to add [the drug] Antabuse to the patients' regular cocktail of AIDS drugs for two weeks, then check their blood after 24 weeks to see whether it has depleted the amount of latent HIV," according to the news service. The trial is expected to conclude in June 2012, according to ClinicalTrials.gov (Bennett, 2/22).
Back to other news for February 2011
This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
|
No comments have been made.
|